Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety

Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety

Chronic migraine is a disabling neurovascular disorder that ranks amongst the top causes of years lived with disability worldwide. The duration and the frequency of migraine affect cognitive and affective domains, inducing worsening of memory, executive functions, orientation and causing anxiety. Po...

Full description

Bibliographic Details
Main Authors: M. T. Corasaniti, G. W. Lawrence, G. Bagetta, R. Iannacchero, A. Tarsitano, A. Monteleone, M. Pagliaro, P. Tonin, G. Sandrini, P. Nicotera, D. Scuteri
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Pharmacology
Subjects:
onabotulinumtoxin A
chronic migraine
anti-CGRP monoclonal antibodies
anti-CGRP-R monoclonal antibodies
erenumab
eptinezumab
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1296577/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1296577/full

Similar Items